Pharmacoeconomic aspects of the treatment of pituitary gland tumours

Wspolczesna Onkologia

Volumn 17, Issue 2, 2013, Pages 137-143

  Sowiński, Jerzy ^a   Sawicka, Nadia ^a   Piatek, Katarzyna ^a   Zybek, Ariadna ^a   Ruchała, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acromegaly; ACTH secreting pituitary adenoma; Lanreotide; Octreo tide; Pharmacoeconomics; Prolactinoma

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE RECEPTOR STIMULATING AGENT; ETOMIDATE; GROWTH HORMONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PERGOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; QUINAGOLIDE; RETINOIC ACID; THYROTROPIN;

ACROMEGALY; ACTH SECRETING ADENOMA; ARTHRITIS; ASTHENIA; CARPAL TUNNEL SYNDROME; CELL PROLIFERATION; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DRUG COST; EDEMA; GROWTH HORMONE SECRETING ADENOMA; HEADACHE; HEALTH CARE; HUMAN; HYPERHIDROSIS; HYPERTRANSAMINASEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; INJECTION SITE PAIN; MORTALITY; NAUSEA; PHYSICIAN; PITUITARY INCIDENTALOMA; PROLACTINOMA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SLEEP DISORDERED BREATHING; THYROTROPIN SECRETING ADENOMA; TREMOR; VASOSPASM; VERTIGO; VOMITING;

EID: 84877725293     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.34616     Document Type: Review

References (58)

1. Ezzat S, Asa SL, Couldwell WT, The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613-9.
2. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72: 377-82.
3. Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 2012 Dec 14 [Epub ahead of print].
4. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011; 14: 284-94.
5. Rostad S. Pituitary adenoma pathogenesis: an update. Curr Opin Endocrinol Diabetes Obes 2012; 19: 322-7.
6. Schopohl J, Strasburger CJ, Caird D, ; German Lanreotide Study Group. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011; 119: 156-62.
7. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; AACE Acromegaly Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly - 2011 update: executive summary. Endocr Pract 2011; 17: 636-46.
8. Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology 2006; 83: 139-44.
9. Marko NF, LaSota E, Hamrahian AH, Weil RJ. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg 2012; 117: 522-38.
10. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-52.
11. Giustina A, Chanson P, Bronstein MD, Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-8.
12. Plöckinger U. Medical therapy of acromegaly. Int J Endocrinol 2012; 2012: 268957.
13. Roemmler J, Schopohl J. Clinical experience with lanreotide for the treatment of acromegaly. Exp Rev. Endocrinol. Metab 2012; 7: 139-49.
14. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Mil - ler KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly - 2011 update. Endocr Pract 2011; 17 Suppl 4: 1-44.
15. Marty R, Roze S, Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices (Auckl) 2012; 5: 39-44.
16. Carmichael JD. Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence 2012; 6: 73-82.
17. Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005; 54: 1276-81.
18. Trocóniz IF, Cendrós JM, Peraire C, Ramis J, Garrido MJ, Boscani PF, Obach R. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet 2009; 48: 51-62.
19. Kelly P, Maher KT, Chew SL, Monson JP, Grossman AB, Jenkins PJ. A single- center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010; 16: 191-7.
20. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006; 65: 320-6.
21. Ronchi CL, Boschetti M, Degli Uberti EC; Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007; 67: 512-519.
22. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 2007; 157: 571-7.
23. Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl) 2012; 5: 103-9.
24. Valentim J, Passos V, Mataveli F, Calabro A. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 2008; 52: 1452-60.
25. Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J, Wall N, Grønbaek H, Florholmen J, Ohberg A, Granberg D. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional. Patient Prefer Adherence 2012; 6: 703-10.
26. Orlewska E, Kos-Kudla B, Sowinski J, The retrospective phase re - sults of observational study Landro-Study assessing resource utilization in the population of polish acromegalic patients treated with Somatuline AUTOGEL. New Medicine 2012; 3/2012: 39-46.
27. Moore DJ, Adi Y, Connock MJ, Bayliss S. Clinical effectiveness and costeffectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 2009; 9: 20.
28. Roelfsema F, Biermasz NR, Pereira AM, Romijn J. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine 2006; 1: 385-98.
29. Karavitaki N, Wass JA. Pegvisomant: a new treatment modality for acromegaly. Hormones (Athens) 2004; 3: 27-36.
30. Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011; 21: 129-33.
31. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534.
32. Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 2010; 10: 10.
33. Molitch ME, Elton RL, Blackwell RE, Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698-705.
34. Maiter D, Primeau V. 2012 update in the treatment of prolactinomas. Ann Endocrinol (Paris) 2012; 73: 90-8.
35. Barlier A, Jaquet P. Quinagolide - a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 2006; 154: 187-95.
36. Molitch ME. Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis? Nat Rev Endocrinol 2011; 7: 254-5.
37. dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 2011; 14: 259-65.
38. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008; 93: 4721-7.
39. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-883.
40. Iyer P, Molitch ME. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract 2011; 17: e55-8.
41. Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 2008; 93: 4643-5.
42. Findling JW, Raff H. Cushing's Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 2006; 91: 3746-53.
43. Arnaldi G, Angeli A, Atkinson AB Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-602.
44. Swearingen B, Biller BM, Barker FG 2nd, Katznelson L, Grinspoon S, Klibanski A, Zervas NT. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 1999; 130: 821-824.
45. Hofland LJ. Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol 2008; 286: 199-205.
46. Fleseriu M, Petersenn S. Medical management of Cushing's disease: what is the future? Pituitary 2012; 15: 330-41.
47. Batista DL, Zhang X, Gejman R, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006; 91: 4482-8.
48. Hofland LJ, van der Hoek J, Feelders R, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endo - crinol 2005; 152: 645-654.
49. Bertherat J, Schopohl J, Ludlam WH, Long-term pasireotide use leads to significant and sustained improvements in the signs and symptoms of Cushing disease: 24-month results from a randomized phase III study. Endocr Rev 2012; 33 (03-MeetingAbstracts): SUN-734.
50. Colao A, Petersenn S, Newell-Price J; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924.
51. Gatto F, Barbieri F, Castelletti L, In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary 2011; 14: 141-7.
52. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009; 42: 361-70.
53. Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J 2007; 54: 371-378.
54. Young WF Jr, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 1996; 71: 649-56.
55. Yamada S, Kovacs K, Horvath E, Aiba T. Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age. J Neurosurg 1991; 75: 902-5.
56. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML; Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 894-904.
57. Donckier JE, Gustin T. Pituitary incidentaloma: to operate or not to operate? Acta Chir Belg 2012; 112: 255-60.
58. Randall BR, Kraus KL, Simard MF, Couldwell WT. Cost of evaluation of patients with pituitary incidentaloma. Pituitary 2010; 13: 383-4.